Pfizer (PFE) Competitors

Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Do analysts prefer PFE or AMGN?

Pfizer currently has a consensus target price of $28.12, suggesting a potential upside of 17.60%. Amgen has a consensus target price of $304.43, suggesting a potential upside of 10.14%. Given Pfizer's stronger consensus rating and higher probable upside, research analysts clearly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.39
Amgen	2 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.32

Is PFE or AMGN a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.2%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.4%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years and Amgen has raised its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media prefer PFE or AMGN?

In the previous week, Pfizer had 27 more articles in the media than Amgen. MarketBeat recorded 78 mentions for Pfizer and 51 mentions for Amgen. Amgen's average media sentiment score of 1.32 beat Pfizer's score of 1.26 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	62 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	42 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, PFE or AMGN?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.63B	2.14	$8.03B	$1.88	12.72
Amgen	$33.42B	4.45	$4.09B	$12.23	22.60

Is PFE or AMGN more profitable?

Amgen has a net margin of 18.96% compared to Pfizer's net margin of 16.84%. Amgen's return on equity of 174.71% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	16.84%	21.42%	9.12%
Amgen	18.96%	174.71%	13.12%

Which has more volatility & risk, PFE or AMGN?

Pfizer has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Do institutionals and insiders believe in PFE or AMGN?

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Amgen beats Pfizer on 11 of the 20 factors compared between the two stocks.